Journal
VACCINE
Volume 26, Issue 3, Pages 430-439Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2007.10.070
Keywords
smallpox vaccination; vaccinia; povidone iodine ointment
Categories
Funding
- NCRR NIH HHS [K01 RR000163, M01 RR000334-380659, RR000163, RR023424, M01 RR000334, RR000334, P51 RR000163, P51 RR000163-486849] Funding Source: Medline
- NIAID NIH HHS [N01 AI040029, HHSN266200400029C] Funding Source: Medline
- PHS HHS [HHSN266200400029] Funding Source: Medline
Ask authors/readers for more resources
One concern with traditional smallpox vaccination is inadvertent spread of virus to atopic or immunocompromised contacts. To reduce this risk, we tested the ability of povidone iodine to inactivate infectious virus at the vaccination site beginning at 7 days after transcutaneous smallpox vaccination. This ointment rapidly inactivated virus on the skin without reducing neutralizing antibody titers or antiviral T cell responses. Moreover, there was no delay in healing/eschar separation following povidone iodine application. Together, this indicates that administration of an antiviral/antimicrobial cream can effectively block virus shedding after traditional smallpox vaccination and reduce the risks of autoinoculation or contact spread. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available